Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.
Syndax Pharmaceuticals, Inc. (SNDX) had Cost of Goods Sold of $1.28M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$37.96M |
|
$-71.85M |
|
|
Cost of Goods Sold |
$1.28M |
$36.68M |
|
$107.31M |
|
$-69.35M |
|
$-2.49M |
|
$-71.85M |
|
$-71.85M |
|
$-71.85M |
|
$-71.85M |
|
$-71.85M |
|
$-71.85M |
|
$-69.35M |
|
$-72.51M |
|
86.34M |
|
86.34M |
|
$-0.83 |
|
$-0.83 |
|
| Balance Sheet Financials | |
$531.68M |
|
-- |
|
$64.47M |
|
$596.15M |
|
$112.99M |
|
$324.41M |
|
$325.74M |
|
$438.73M |
|
$157.42M |
|
$157.42M |
|
$157.42M |
|
86.06M |
|
| Cash Flow Statement Financials | |
$-182.96M |
|
$136.03M |
|
$1.48M |
|
$154.30M |
|
$108.85M |
|
$-45.45M |
|
$24.17M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.71 |
|
-- |
|
-- |
|
0.67 |
|
2.18 |
|
96.63% |
|
-182.71% |
|
-182.71% |
|
-- |
|
-189.28% |
|
-189.28% |
|
$-182.96M |
|
-- |
|
-- |
|
-- |
|
0.06 |
|
0.07 |
|
1.07 |
|
83.93 |
|
-45.64% |
|
-45.64% |
|
-12.05% |
|
-14.91% |
|
$1.83 |
|
$-2.12 |
|
$-2.12 |
|